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ABSTRACT
CFTR expression is tightly controlled by a complex
network of ubiquitous and tissue-specific cis-
elements and trans-factors. To better understand
mechanisms that regulate transcription of CFTR,
we examined transcription factors that specifically
bind a CFTR CArG-like motif we have previously
shown to modulate CFTR expression. Gel mobility
shift assays and chromatin immunoprecipitation
analyses demonstrated the CFTR CArG-like motif
binds serum response factor both in vitro and
in vivo. Transient co-transfections with various SRF
expression vector, including dominant-negative
forms and small interfering RNA, demonstrated that
SRF significantly increases CFTR transcriptional
activity in bronchial epithelial cells. Mutagenesis
studies suggested that in addition to SRF other co-
factors, such as Yin Yang 1 (YY1) previously shown
to bind the CFTR promoter, are potentially involved
in the CFTR regulation. Here, we show that func-
tional interplay between SRF and YY1 might provide
interesting perspectives to further characterize the
underlying molecular mechanism of the basal CFTR
transcriptional activity. Furthermore, the identif-
ication of multiple CArG binding sites in highly
conserved CFTR untranslated regions, which form
specific SRF complexes, provides direct evidence
for a considerable role of SRF in the CFTR transcrip-
tional regulation into specialized epithelial lung cells.
INTRODUCTION
Expression of the cystic ﬁbrosis transmembrane conductance
regulator(CFTR)gene occursinasubsetofspecializedcellsof
epithelial origin (1–3) and is tightly regulated both temporally
and spatially (4,5). However, no clear mechanism responsible
for this regulation has yet been reported in part due to the com-
plexity of the non-coding regions structure of the CFTR gene.
Despite the absence of a TATA element, the transcription of
the CFTR gene may be initiated through several discrete start
sites(6,7),includingthosethataretissue-speciﬁc(8).Anintact
CCAAT consensus is also required for accurate transcript
initiation (9). Both basal and cAMP-mediated regulation of
CFTR transcription involve a weak cAMP response element
(CRE) nucleotide consensus (10,11) in tandem with a con-
sensus inverted CCAAT element or Y box (9). In addition,
CFTR transcription may be modulated by additional overlap-
ping cis-acting elements, including a polymorphic YY1 site,
located in the human minimal CFTR promoter (12). CFTR
promoter activity may be enhanced by exogenous transfected
NF-kB via its binding to the –1103 kB element (13). CFTR
expression is also regulated through interactions with factors
involved in remodeling of chromatin structure, such as
CDP/cut and hGCN5 (14).
Because none of these cis-acting elements confers tissue-
speciﬁc control of CFTR expression, several studies focused
on identifying potential regulatory elements that lie
mainly outside the coding region. Extensive analyses of the
chromatin structure identiﬁed multiple clusters of DNase I-
hypersensitive sites (DHSs) (15,16), some of which contain
tissue-speciﬁc enhancer elements (17,18). Multiple binding
sites for a tissue-speciﬁc transcription factor, called
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doi:10.1093/nar/gki837HNF1a, recently identiﬁed in various DHS core, modulate
likewise CFTR expression (19). Despite extensive studies,
the transcriptional regulatory networks of CFTR expression
remain to be unraveled.
Our current model for the regulation of human CFTR
expression proposes that multiple transcription factors interact
with previously reported polymorphic and composite cis-
acting elements encompassing a CArG-like motif (12,20).
The CArG box (CC(A/T)6GG), originally deﬁned as the
core component of the serum response element (SRE), is
found in the 50 region of immediate early response genes,
such as c-fos (21), and in many muscle-speciﬁc gene pro-
moters (22). This DNA element binds serum response factor
(SRF), highly regulated and interactive transcription factor,
whichisphylogeneticallyconservedandbelongstotheMADS
box family of proteins, with MCM1, Agamous, Deﬁciens
and SRF (23). Although SRF is particularly enriched in
skeletal, cardiac and smooth muscle lineages (24,25), it is
also expressed in a variety of human cell lines from distinct
tissue origins (26), and, to a lesser extent, in ectoderm-derived
tissue such as gastric epithelium (27). Interestingly, it has been
shown that Drosophila SRF homolog is expressed in a subset
of tracheal cells and regulates cytoplasmic outgrowth during
terminal branching of the tracheal system (28). Hence, it has
been suggested that SRF plays an essential role in the forma-
tion of the respiratory system. Moreover, it has been recently
shown that SRF is involved in myoﬁbroblast differentiation
during lung damage (29). Therefore, we hypothesized that
trans-acting factors interacting with CArG-like motif, such
as SRF, could be important in CFTR expression regulation.
We provided evidence that SRF is expressed in bronchial
epithelial cell expressing endogenous CFTR protein. Through
the use of combined gel mobility shift–chromatin immuno-
precipitation (ChIP) assays, we ﬁrst demonstrated that SRF
protein binds, both in vitro and in vivo, the CFTR minimal
promoter region spanning the CArG-like motif. Mutagenic
studies and transient co-transfections experiments showed
that SRF alone is not sufﬁcient to transactivate the CFTR
gene. Upon some mutations of the CFTR-CArG-like element,
promoter activity is severely decreased, potentially implying
YY1 as a co-repressor. Given the YY1 well-deﬁned role in the
transcriptional regulation of some SRE-dependent promoters
(30–33), we explored the putative role of YY1 on the CFTR
promoter activity and demonstrated functional interplay
between this factor and SRF. Finally, by stringent in silico
structural analysis, we identiﬁed additional multiple near con-
sensus CArG sites within the highly conserved promoter and
intronic regions of the CFTR gene. We also documented the
existence of SRF-containing protein complexes on numerous
predicted CFTR CArG-like elements. Taken together, the data
obtained classify CFTR as a novel SRF target gene, subject to
modest but signiﬁcant SRF activation, and open the gate to
further investigate how SRF may be involved in the regulation
of CFTR gene expression.
MATERIALS AND METHODS
Cell culture
Humanbronchialepithelialcells,Beas2BandA549expressing
endogenous CFTR were kindly provided by Dr Marc Chanson,
Department of Pediatrics, Laboratory of Clinical Investiga-
tion, Switzerland. Beas2B and A549 cells were maintained
in high glucose DMEM (4500 mg/l D-Glucose, Invitrogen
Corporation) supplemented with 10% fetal bovine serum
(FBS) (Eurobio, France) and 5 mM L-glutamine. C2C12 myo-
blasts were grown in DMEM supplemented with 10% FBS
and 5 mM L-glutamine. All cell cultures, supplemented with
100 U ml
 1 penicillin and 100 mg ml
 1 streptomycin, were
maintained at 37 C under 5% CO2. As positive or negative
controls for the different assays, other cells used in this study
included colon adenocarcinoma Caco-2 cell line (ECACC)
with functional CFTR (34,35) and normal monkey kidney
ﬁbroblast-like COS-7 cell line (ATCC) which does not
express CFTR (36,37); all were maintained in DMEM
supplemented with FBS and were incubated in the same
conditions as above.
Plasmids constructs
The original luciferase expression vector pGL3-Basic con-
taining the wild-type human CFTR minimal promoter was
described previously (12). To further study the putative com-
posite cis-acting element located at –108 from the major tran-
scription initiation site of the human CFTR promoter (38), the
CFTR-CArG-like motif was either mutated in a consensus
CArG box or in a degenerated motif. Mutations were intro-
duced into the WT-pGL3 plasmid using an oligonucleotide-
directed mutagenesis system (QuickChange Site-Directed
Mutagenesis Kit, Stratagene) according to the manufacturer’s
instructions. Mutagenesis primers are depicted in Table 1.
The presence of mutations and sequence ﬁdelity were
veriﬁed by dideoxynucleotide sequencing. For each intro-
duced mutation the loss or the improvement of transcription
factor binding activity was checked by in vitro assays.
The 3xSRE-fos TATA-luciferase reporter construct was
kindly provided by R. A. Hipskind, Institut de Genetique
Moleculaire, Montpellier, France. Expression vectors encod-
ing either human wild-type SRF, the pHiv-SRF or SRF
dominant-negative form deleted of an essential part of
DNA-binding domain (DBD), the pHiv-DN, were generously
given by D. Trouche, Laboratoire de Biologie Moleculaire
Eucaryote, Toulouse, France. Another dominant-negative
SRF mutant, pHiv-DBD, was constructed by PCR ampliﬁca-
tion of SRF fragment spanning the DBD ﬂanked by HindIII
and HincII sites to facilitate cloning into expression vector.
The PCR was performed using pHiv-DBD-SRF primers(listed
in Table 1), 10 ng of SRF expression vector, 200 mMo f
each dNTP, 0.5 mM of each primer and 1.5 U Taq DNA
polymerase (Perkin Elmer, Inc.) in a 1· reaction buffer pro-
vided by the manufacturer. TranSilent human control siRNA
vector and TranSilent  human SRF siRNA vector (catalog
no. SR1038) were purchased from Panomics. Expression vec-
tors encoding either pCMV-YY1 or pcDNA3-YY1 were gen-
erously provided by E. Seto, E. Bonnefoy and A. Moustakas,
respectively.
Transient transfections
Cells were seeded at a density of 200000 cells/2 ml of medium
and plated in 6-well dishes (NUNClone , Merck-Eurolab,
Inc.). After a culturing period of 24 h, cells were transfected
with PolyFect  transfection reagent (Qiagen Corporation,
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For transient transfection, we used 1.8 mg of plasmid reporter
and 0.2 mg of internal control pRL-SV40 containing Renilla
luciferase (Promega Corporation). The pGL3-Basic vector
lacking both eukaryotic promoter and enhancer sequences
was used as a negative control. After 48 h, the luciferase
activity was evaluated with the Dual Luciferase Reporter
Assay System (Promega Corporation), as described pre-
viously (12). Luminescence measurements were performed
on a Luminoskan Ascent luminometer (ThermoLabsystem
Corporation, France). Fireﬂy luciferase activity was normal-
ized to Renilla luciferase activity. All luciferase activities
represent at least three independent experiments with each
construct tested in triplicate per experiment. Luciferase activ-
ity data are expressed as the means ± SD computed from the
results obtained from each set of transfection experiments. To
minimize the possibility of errors in DNA ampliﬁcation,
at least two independently constructed clones were tested.
For co-transfection assays, unless otherwise indicated, 1.8 mg
of luciferase reporter and 1–2 mg of each expression vector
were used. Transfection with siRNA was performed using
Lipofectamine 2000 (Invitrogen) with 2.5 mg of siRNA. The
cells were transfected with CFTR promoter plasmid reporter,
and luciferase activity was determined as described above.
Aliquots of cell lysates were used for western blotting to
conﬁrm the speciﬁcity and level of SRF protein knockdown.
Preparation of whole cell proteins, nuclear extracts
and recombinant protein production
For the CFTR immunodetection analyses, Beas2B, A549,
C2C12, COS-7 and Caco-2 cells were treated with 5 mM
sodium phenylbutyrate, which has been previously reported
to increase CFTR (39) and scraped into lysis buffer (50 mM
Tris–HCl, 1% NP-40, 40 mM beta-glycerophosphate and
120 mM NaCl) supplemented with protease inhibitors [1 mM
phenylmethylsulfonyl ﬂuoride (PMSF), 1 mM DTT, and
1 mg/ml aprotinin, leupeptin and pepstatin]. Nuclear extracts
were prepared usingthe Nuclearextraction kit accordingtothe
procedure recommended by the supplier (Panomics, Ozyme,
France). Protein concentrations were determined using the
Bio-Rad Protein Assay kit with BSA as a standard, based
on the classical Bradford method. The pGEX-SRF plasmid,
a generous gift from D. Trouche (Laboratoire de Biologie
Moleculaire Eucaryote), was used for protein expression.
GST–SRF fusion protein was puriﬁed from Escherichia coli
as described previously (40). The purity and concentration of
protein samples were estimated by SDS–PAGE.
Electrophoretic mobility shift assay (EMSA)
and supershifts
Oligonucleotides probes were synthesized corresponding to
CFTR CArG-like element and mutant versions in which the
Table 1. Sequences of oligonucleotides
Primer sequence Annealing temperature
RT–PCR primers (50!30)
Hprt human forward TGT AAT GAC CAG TCA ACA GGG 52 C
Hprt human reverse TGA CCA AGG AAA GCA AAG TCT G
SRF forward CTA CCA GGT GTC GGA GTC TGA 52 C
SRF reverse CCA GAT GAT GCT GTC AGG AAC A
CFTR external primers forward 729 TTT CGT GTG GAT CGC TCC TT 57 C
CFTR external primers reverse 1487 TCC AGC AAC CGC CAA CAA CT
CFTR external primers forward 757 GCA CTC CTC ATG GGG CTA ATC T 59 C
CFTR external primers reverse 1436 TTC AGG ACA GGA GTA CAA AGA A
Expression vector construct primers (50!30)
a
pHiv-DBD-SRF forward AAG CTT ATG AGC GGG GCC AAG CCG GG 65 C
pHiv-DBD-SRF reverse GTC AAC TCA GAA CGC CGG CTT CAG TGT G
Chromatin immunoprecipitation primers (50!30)
Negative control
b-Globin forward GCT TAC CAA GCT GTG ATT CC
b-Globin reverse AAG CAA TAG ATG GCT CTG CC 54 C
Positive control
b-Actin forward ATG CTG CAC TGT GCG GCG AA
b-Actin reverse GTC GCG CCG CTG GGT TTT AT 64 C
Target sequence CFTR minimal promoter
CFTR-CArG-like forward GGC TCG AGG CTG GGA GTC AGA ATC GG
CFTR-CArG-like reverse TTC CAT GGT CTC TCG GGC GCT GGG GT 70 C
Target sequence: CArG located at 2373 bp of the CFTR promoter
CArG3 forward GTT AAA GCT CTG AAT AAT GC 54 C
CArG3 reverse CAC ACA TGT ACA TAG GAA GA
Site-directed mutagenesis primers (50!30)
b
C2 GAA AGC CGC TAG ACC AAA TTT GGG GCC GGA CC
C3 GAA AGC CGC TAG ACC AAA TAT GGG GCC GGA CC
C4 GAA AGC CGC TAG ACCA TA TTT GGG GCC GGA CC
C5 GAA AGC CGC TAG ACCA TAT AA GGG GCC GGA CC
D1 GAA AGC CGC TAG AGC AAA TIT GTG GCC GGA CC
D2 GAA AGC CGC TAG AGC ACG TTT GTG GCC GGA CC
D3 GAA AGC CGC TAG AGC AAA TATG TG GCC GGA CC
D4 GAA AGC CGC TAG AGC ACG TATG TG GCC GGA CC
aBold type indicates the restriction sites: HindIII and HincII.
bBold and italicized type indicates mutated nucleotides.
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ted. The oligonucleotide sequences were listed in Table 2.
Single-stranded complementary oligonucleotides containing
the studied sequences were annealed, end-labeled with
[g-
32P]ATP (5000 Ci/mmol) and puriﬁed as described previ-
ously (12). Mobility assay conditions were speciﬁcally optim-
ized for binding of SRF. The binding reaction was carried out
in a total volume of 20 ml containing 2 ng ( 30000 c.p.m.) of
the labeled probe, 10 ml of binding buffer (2·), 0.25 mg
poly(dI–dC) (Amersham Pharmacia) used as a non-speciﬁc
competitor, 5–12 mg of nuclear extracts and 100–1000 ng
of GST–SRF fusion chimera protein. For EMSA competition
and antibody interference assays, proteins were incubated
with either cold speciﬁc competitors (WT and SRE oligo-
nucleotides, see Table 2), unspeciﬁc competitor (GATA
oligonucleotide, see Table 2) or puriﬁed antibodies (anti-
SRF: sc-335X; anti-YY1: sc-1703X or anti-HA, Santa Cruz,
Biotechnology Inc., TEBU, France) for 20 min before addition
of labeled probes. After incubation of 30 min at room
temperature, complexes were resolved on 5% acrylamide:
bisacrylamide (29:1) native gel containing 0.5· TBE at
26 mA for 1 h.
Formaldehyde cross-linking and
chromatin immunoprecipitation
Beas2B and A549 cells proteins were cross-linked to DNA by
adding formaldehyde to a ﬁnal concentration of 1% for 10 min
at 37 C. The ﬁxed cells were prepared for immunoprecipita-
tion using the protocol of ChIP assay kit (Upstate Biotechno-
logy Inc., Euromedex, France) with minor modiﬁcations.
Cells were resuspended in 1 ml cold phosphate-buffered saline
(PBS), pelleted by centrifugation and lysed in 800 mlo fS D S
lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris–HCl,
pH 8.1) containing protease inhibitors (1 mM PMSF, 1 mg/ml
aprotinin and 1 mg/ml pepstatinA). After incubation on ice for
10 min, the cross-linked chromatin was sheared by sonication
at the following conditions eight times for 10 s at 40% of
maximum power and diluted 10-fold in ChIP dilution buffer
(0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM
Tris–HCl, pH 8.1 and 167 mM NaCl) with protease inhibitors.
Aliquots containing 20 ml of each aliquot were used as a
control to show total input DNA. The chromatin solution
was precleared with 80 ml of salmon sperm DNA/protein A
agarose-50% slurry (Upstate Biotechnology Inc.) for 1 h at
4 C under agitation, and subsequently incubated at 4 Co na
rotating stand overnight with either 3 ml of anti-SRF antibody
(sc-335X, Santa Cruz, Biotechnology Inc.) or an irrelevant
antibody (anti-HA). Immune complexes were precipitated
by the addition of 60 ml of salmon sperm DNA/protein A
agarose and incubated at 4 C for 1 h and low speed spinning.
Precipitates were washed once with 1 ml of low salt buffer,
once with high salt buffer, once with LiCl buffer and twice
with1·TE, according tothemanufacturer’srecommendations
(Upstate Biotechnology Inc.). The cross-links were reversed
by the addition of 20 ml of 5 M NaCl and incubation at 65 C
overnight. The samples were treated with proteinase K,
phenol–chloroform extracted, ethanol precipitated and resus-
pended in 30 ml of sterile water. PCR analysis was carried out
using primers from different regions of the human CFTR pro-
moter and as additional controls from promoter regions of a
number of genes that are either silent (b-globin) or having at
least one functional CArG element (b-actin). The sequences
of PCR primers are listed in Table 1. After 45 cycles of
ampliﬁcation, PCR products were separated on 1.8% agarose
gels and visualized by ethidium bromide staining and
UV transillumination.
Reverse transcriptase–PCR
Total RNA from epithelial cells (Beas2B and A549), myo-
blasts (C2C12) and ﬁbroblasts (COS-7) was isolated using the
SV Total RNA Isolation System  (Promega, France). Reverse
transcription was performed with 3 mg of total RNA, 300 ng of
random hexamers (Invitrogen Corporation), 10 mM dNTPs,
1 ml of RNasin RNase inhibitor (Promega), 2 ml of DTT at
0.1 M, 4 ml of ﬁrst strand buffer (Invitrogen), 200 U of
M-MLV RT (Invitrogen) and nuclease-free water (Promega)
in a ﬁnal reaction volume of 20 ml. For each RNA template,
a control reaction without RT was included. For each RT
reaction condition, an H2O no-template reaction was included
as an additional negative control. The reaction mixture was
incubated ﬁrst for 10 min at 25 C, then 40 min at 42 C; this
was followed by a heat inactivation step of 72 C for 3 min.
Aliquots containing 1 ml of the cDNA synthesis reaction
mixture were used for PCR analyses. The expression level
of SRF mRNA was analyzed by PCR ampliﬁcation of
the endogenous Hypoxanthine PhosphoRybosyl-Transferase
(HPRT) gene used as internal control. Ampliﬁcation mixture
Table 2. Ologonucleotides used in EMSA analysis
Oligonucleotides (50!30)
SRE
a GG ATG TCC ATA TTA GGA CAT CT
GATA
b CGG CCC CTA TCG GGA CGC AGC ACC TGG CGC CGA
WT
c GAA AGC CGC TAG AGC AAA TTT GGG GCC GGA CCA GGC AGC
C1
d,
e GAA AGC CGC TAG AGC AAA TAT GGG GCC GGA CCA GGC AGC
C2
e GAA AGC CGC TAG ACC AAA TTT GGG GCC GGA CCA GGC AGC
C3
e GAA AGC CGC TAG ACC AAA TAT GGG GCC GGA CCA GGC AGC
C4
e GAA AGC CGC TAG ACCA TA TTT GGG GCC GGA CCA GGC AGC
C5
e GAA AGC CGC TAG ACCA TAT AA GGG GCC GGA CCA GGC AGC
D1
f GAA AGC CGC TAG AGC AAA TTT GTG GCC GGA CCA GGC AGC
D2
f GAA AGC CGC TAG AGC ACG TTT GTG GCC GGA CCA GGC AGC
D3
f GAA AGC CGC TAG AGC AAA TATG TG GCC GGA CCA GGC AGC
D4
f GAA AGC CGC TAG AGC ACG TATG TG GCC GGA CCA GGC AGC
CArG 1 AAC ATT CAT CCA TGT CCT TAT GTG GCT TGT AGT TCA TTA
CArG 2 TTG TCA TAA TAA TTG GCA TAT ATG GTA AGT GAC CAA CAA
CArG 3 TTT ATT TCT ACC AAA ACA AAT TTG GGC TGT AAT GTT TTA
CArG 4 TTA ACT GAG CTT GGC CCA CAT ATG GTG TAG TGA CAT GCT
CArG 5 CAA CTG TCA GGT AGC AAT ATA TGA TGG AAG AAG CAT GTA
CArG 6 ATT TCT ATT TTG TTC CTA TAT TAG GCC AAG GAG AGG TGG
CArG 7 TTG AAC TGA ACT GGC CAT TTA TGG GAA AGG TCA CTG GGT
CArG 8 ATC CTT GGT TGT AAC CTA TAA AAG GAG ACA GAT TCA AGA
CArG 9 AAC CTG GAA GAT CTC CCA AGT ATG GGG GAA GGT TTC ACC
CArG 10 CCA AAT GAT ACT TGA CCA AAT TTG TCC CTT TGG CTT GTT
Bold and italicized type indicates mutated nucleotides. The CArG boxes in the
CFTR minimal promoter are shaded. The underlined nucleotides indicate the
insilicopredictedCArGelementsinthenon-codingregionsoftheCFTRgene.
ac-fos consensus SRE (56).
bOligonucleotide for competition assay, the GATA and E-box sequences are
boxed (85).
cCArG-like box located in the human minimal CFTR promoter region.
dCArG-likebox locatedin the human minimal CFTR promoterregion contain-
ing the naturally occurring variant [ 102T>A] (12).
eConsensus CArG box with minimal CFTR promoter flanking sequences.
fMutated CArG box with minimal CFTR promoter flanking sequences.
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10 pmol of each HPRT-speciﬁc primer, 1.5 U of AmpliTaq
polymerase (Applied Biosystem Corporation) and nuclease-
free water (Promega) in a 25 ml volume. Ampliﬁcation was
performed with an initial denaturation step at 95 C for 5 min,
followed by 35 cycles of 30 s of 95 C denaturation, 60 s of
52 C annealing and 2 min extension at 72 C. Ampliﬁcation
of CFTR was performed as described previously (41). The
RT–PCR products were separated on an 8% non-denaturing
polyacrylamide gel, stained with ethidium bromide. To ensure
that the sequence of cDNA products derived from both
SRF and CFTR RT–PCR analyses correspond to respective
published sequences, the cDNA bands were puriﬁed and
prepared for dideoxy DNA sequencing. Controls included
RNA preparations from monkey kidney ﬁbroblasts (COS-7),
which are negative for CFTR expression (36,37).
Western blot analysis
Twenty-ﬁve microgram protein extracts (except where other-
wise indicated) were resolved on a 10% (except where other-
wiseindicated)SDS–polyacrylamidegelandtransferredontoa
nitrocellulose membrane (except where otherwise indicated).
All membranes were Ponceau S stained to ensure sample
integrity. Brieﬂy, the membranes were blocked with 5%
skim milk in PBS supplemented with 0.01% Tween-20 and
incubated with diluted primary antibodies in 5% skim milk
(1:5000 diluted anti-SRF Abs: sc-335X and sc-25290X pur-
chased from Santa Cruz; 1:1000 diluted anti-CFTR Ab: 24.1
from R&D System; 1:2500 diluted anti-b-actin antibody:
AC-15 from Sigma, 1:2500 diluted anti-b-tubulin antibody:
T6074 from Sigma) overnight. The membranes were then
washed and incubated with an appropriate horseradish peroxi-
dase (HRP) conjugated secondary antibody at 1:15000 in
PBS-5% milk. The membranes were reacted with chemilu-
minescence reagent ECL (Roche Diagnostic) as described by
the manufacturer and subsequently exposed to Biomax photo-
graphic ﬁlm (Kodak Corporation). The protein levels of
the actin housekeeping gene (except where otherwise stated)
were assayed for internal control of protein loading.
Indirect immunofluorescence
A549, Beas2B, C2C12 and COS-7 cells were plated on
Lab-Tek II CC2  Chamber Slide  systems (Nalge Nunc)
1 day before immunohistochemical analysis. The cells were
ﬁxed and permeabilized in 4% paraformaldehyde and 0.1%
Triton X-100, respectively, for 20 min durations at room tem-
perature. Non-speciﬁc binding sites were blocked with 1%
BSA in PBS for 1 h. The cells were subsequently incubated
with primary antibodies diluted in 1:100 in PBS–BSA. Anti-
bodies used included, the clone L12B4 (Upstate biotechno-
logy), an anti-CFTR antibody known to recognize human,
rat, mouse and bovine CFTRs (42) and the H-300 or the
A11 anti-SRF antibody (sc-13029 and sc-25290, Santa
Cruz). The speciﬁcity of the anti-CFTR antibody has been
described previously (43,44) and was also veriﬁed by using
a CFTR-positive human Caco-2 cell line (34,35). For nuclear
counterstaining, DAPI (sc-3598, Santa Cruz) was applied at
a concentration of 1:5000. Cells were then washed with PBS–
BSA and incubated with either donkey anti-rabbit ﬂuorescein
isothiocyanate-conjugated (FITC) or donkey anti-mouse
Cy3  conjugated secondary antibody (Jackson Immuno-
Research Laboratory Inc.) diluted 1:200 for 1 h at room tem-
perature. Cells were washed twice with PBS–BSA, once with
PBS,andmountedwith Dakocytomationﬂuorescentmounting
medium (Dakocytomation). Indirect immunoﬂuorescence was
examined with an inverted Leica DMR microscope (Leica
Microsystemes SAS). Final images were further processed
using Adobe Photoshop 7.0 software.
Statistical analyses
Transfection data are expressed as the mean ± SE. Paired
comparisons were made using student’s t-test. Data were con-
sidered statistically signiﬁcant at P < 0.05. All graphical data
and statistical analyses were generated with GraphPAD Prism
software (Version 3.0). Densitometric analysis was performed
using computerized densitometry and ImageQuant
TL v.3.0
software (Amersham Biosciences). Densitometric values for
both transcript and protein bands were determined in areas
of equal size and are reported in normalized arbitrary units
relatives to the expression of either HPRT gene or actin protein
set to 1 (except where otherwise indicated).
Computational analyses
The computer program ConSite (http://www.phylofoot.org/),
particularly suited to the analysis of large genomic sequences,
was used to identify putative CArG binding sites within the
promoter and intronic regions of the human CFTR gene. The
algorithm AliBaba 2.1 (http://www.alibaba2.com/) was then
used to verify these predictions and minimize false negatives
or positives. To prevent a possible bias introduced by palin-
dromic or internally repetitive cis-regulatory elements, over-
lapping matches, including on opposite DNA strands, were
deﬁned as a single match.
To assess the importance of the putative CArG elements
identiﬁed in the non-coding regions of the human CFTR gene,
we performed multiple sequence alignments. The human,
cynomolgus, gibbon, squirrel monkey, rabbit, pig, sheep and
cow sequences were aligned using the ClustalW global align-
ment tool (http://clustalw.genome.ad.jp/) (45). The gap open
and extension penalties were set at 15 and 6.66, respectively,
and sequence delay divergence of 30% with a DNA transition
weight of 0.5 was used.
RESULTS
CFTR minimal promoter region encompassing the
CFTR-CArG-like element is remarkably conserved
To search the cis-acting elements involved in the CFTR gene
expression regulation, we previously performed an in silico
search for transcription factor binding sites (46), and reported
that the human minimal CFTR promoter contains a CArG-like
motif, which is localized –108 bp upstream of the major tran-
scription initiation start site (38). Because so far all described
CArG-box elements were found in the regulatory regions of
immediate early genes (47) and in muscle-speciﬁc genes (22),
we conﬁrmed our ﬁrst binding site prediction by using
two other algorithms, AliBaba (http://www.alibaba2.com/)
and ConSite (http://clustalw.genome.ad.jp/). As shown in
Figure 1A, the CFTR-CArG-like element sequence
Nucleic Acids Research, 2005, Vol. 33, No. 16 5275(GC(A/T)6GG) diverges slightly at the 50 from the published
SRF consensus sequence (CC(A/T)6GG) (22,37). However,
this divergence is similar to that observed in the smooth
muscle-gamma-actin promoter which has been demonstrated
to bind SRF (48).
To assess the putative functional importance of CFTR-
CArG-like binding site, we used an orthogonal approach
of deducing regulatory elements by considering orthologous
CFTR minimal promoter regions from several mammal-
ian species representing the Primates, Artiodactylia and
...GGGTGGAGAAAGCCGCTAGAGCAAATTTGGG-CCGGACCAGGCAGCACT...
...GGGTGGAGAAAGCCGCTAGAGCAAATTTGGGGCCGGACCAGGCAGCACT...
...GGTTGGAGAAAGCCGCTAGAGCAAATTTGGGGCCGGACCAGGCAGCACT...
...GGGTTGAGAAAGCCGCTAGAGCAAATTTGGGGCCGGACCAGGCAGCACT...
...---TGGAGAAAGCCGCTAGAGCAAATTTGGGGCTGGATCAGACAGCGTC...
...GGGTGGAGAAAGCCGCTAGAGCGGATTTGAGGCCCGGCCGGGCAGCGCC...
...GGGTGGAGAAAGCCGCTAGAGCGGATTTGAGGCCCGGCCGGGCAGCGCC...
95%
96%
89%
78%
80%
80%
75%
human/species homology 
of the CFTR minimal 
promoter
...GGGCGGAGAAGGAGGCTGGAGCGAATGTGGGGCCGG-CCAGGCAGCACC...
100%
A
B
Figure 1. Cross-species comparison of the CFTR-CArG-like element. (A) Visualization of consensus CArG binding site: pop-up window containing information
about SRF transcription factor obtained from in silico analysis performed with the ConSite tool. (B) Detailed alignment view of the CArG-like element-including
regionofhumanCFTRminimalpromoterwithsevenorthologoussequences:Cynomolgus,Gibbon,SquirrelMonkey,Rabbit,Pig,SheepandCow.Dashesindicate
gaps that were introduced to maximize alignment. Each sequence is represented by a classical text representation with each nucleotide assigned its own color (A is
colored in red, C in blue, G in green and T in black). The numberings above the Cynomolgus sequence are indicated according to the major human transcription
initiationsite.Intheleftpanel,thephylogeneticrelationshipsbetweenthedifferentspeciesareillustratedinarootedtree,directlyderivedfromClustalWprogram.In
the right panel,human/species homologiesare indicated.The accession numberof each CFTR genomic sequenceis indicatedbelow each species name,in brackets
and bold characters. The human CFTR-CArG-like motif is noted above the Cynomolgus sequence.
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gies was carried out using ClustalW multiple CFTR sequence
alignments according to the numerous alignment parameters
described previously (49). Consistent with previous studies
(50,51), we showed that the human minimal CFTR promoter
is remarkably conserved across the orders studied (Figure 1B,
right panel). We found that the CFTR-CArG-like element is
conserved within all the Primates species studied and also
within the pig while, within the sheep, cow and rabbit species,
some substitutions occur in the middle of the CArG-like motif
(Figure 1B). These data are consistent with previous CFTR
promoter phylogenetic work that identiﬁed two types of
regulatory elements: some are conserved between species,
such as a non-consensus CRE at positions –0.1 kb relative
to ATG and some are species-speciﬁc elements, such as a
300 bp purine.pyrimidine (Pu.Py) stretch that is present
only in rodents (50).
Bronchial epithelial expression of SRF
Because we could not previously identify SRF binding to the
CFTR CArG-like element, even though an anti-SRF antibody
had been used (12), we asked whether SRF, mainly described
as highly expressed in muscle cells, was also present in epi-
thelial cell lines. To measure the expression levels of SRF
mRNAs, we used a RT–PCR-based procedure previously
described by Davis et al. (52). As reverse-transcribed control,
the Hypoxanthine PhosphoRybosyl-Transferase (HPRT)
housekeeping gene was ampliﬁed. Ampliﬁcation of SRF from
bronchial epithelial cells and myoblasts yielded a fragment of
the same size, 651 bp (Figure 2A), as that of the full-length
SRF transcript produced by RT–PCR from human hearts (52).
The 453 bp band corresponding to SRF lacking exon 5
(SRFD5) was only detected in the C2C12 myoblast line
(Figure 2A). To ensure that these bands were not the result
of a PCR artifact or genomic contamination of samples, neg-
ative controls such as exclusion of RT or RNA during cDNA
synthesis were included in each assay. As expected, no PCR
product appeared when either RT or the template was omitted
(Figure 2A). Densitometric analysis revealed that bronchial
epithelial cells contained an appreciable amount of SRF
mRNA. Nuclear extracts from A549, Beas2B and C2C12
cells were electrophoresed and then assayed by western blot-
ting with anti-SRF antibody reported to recognize all four
isoforms of the protein (52). As shown in Figure 2B, we
found that robust expression of a 67 kDa band, that based
on molecular mass, corresponds to full-length SRF (SRF-FL)
in all of the cell lines examined. Consistent wit RT–PCR
analysis, a 57 kDa band corresponding to SRFD5 was only
detected in the C2C12 myoblast line. As a control, we checked
the b-actin levels (Figure 2B). Densitometric analysis of west-
ern blot revealedno apparent difference in the expression level
of SRF proteins between the myoblasts and epithelial cells
(Figure 2B). In subsequent western blot analyses in which
parallel blots were probed with only the secondary antibody,
no band was detected (data not shown), thus conﬁrming that
these bands are indeed speciﬁc for SRF. As further evidence,
A549, Beas2B and C2C12 cells express relatively large
amounts of SRF, the cell lines were assessed by indirect
immunoﬂuorescence labeling. A similar staining pattern
was noted in the bronchial epithelial cells and myoblasts
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Figure 2. Bronchial epithelial expression of SRF. (A) Detection of SRF and
HPRT transcripts from both bronchial epithelial and myoblast cell lines by
RT–PCR analysis. Total RNAs isolated from A549, Beas2B and C2C12 cells,
as indicated, were reverse transcribed with random hexamers and PCR ampli-
fied with SRFor HPRT primers.Amplifiedproducts were directlystained with
bromide ethidium on non-denaturing polyacrylamide gel. Expected size of
PCR products is given at left of each transcript. Negative controls are noted
as follow: No RT for the absence of reverse transcriptase and No RNA for an
H2O no-template reaction. Densitometric analysis of SRF bands intensity
was performed with relative HPRT mRNA expression in C2C12 myoblasts.
(B) Western blot analysis of nuclear extracts prepared from both epithelial and
myoblast lines. Each extract (25 mg) was separated by SDS/PAGE (10%) and
westernblottedusingananti-SRFAb.Relativemass,inkilodaltons,isindicated
alongside. As a control for proteins loading in SDS–PAGE, an anti b-actin Ab
was used in western blot. Numbers below the b-actin panel indicate densito-
metricvaluesofthetotalSRFbandsnormalizedoverthecorrespondingb-actin
bands and expressed relative to the C2C12 controls bands, which are set to 1.
(C) The A549, Beas2B and C2C12 cells (rows A, B and C, respectively) were
grown on coverslips, fixed and subjected to indirect immunofluorescence with
anti-SRF Ab. Left panel, cells were stained with FITC-conjugated secondary
antibody (green). Middle panel, cells were counterstained with DAPI (blue)
for nuclear staining. Right panel, shown is merge of SRF immunostaining and
DAPI.RowD,backgroundimmunofluorescenceobtainedintheabsenceofthe
primary antibody.
Nucleic Acids Research, 2005, Vol. 33, No. 16 5277(Figure2C,rowsA–C).Thenucleihave beenstainedblue with
DAPI. As negative control, no staining was detected when the
primary antibody was omitted (Figure 2C, row D). Consistent
with other studies reporting that SRF is ubiquitously expressed
in a variety of cell types (26,27,53), our SRF expression
studies demonstrated that human SRF gene is expressed in
bronchial epithelial cells.
SRF binds the CFTR-CArG-like element
Because the CArG box is not only found in the regulatory
regions of many muscle-speciﬁc genes but also located at the
center of other SREs (54) and forms the core binding site for
SRF (55), we have attempted to determine whether or not
SRF binds to the CFTR-CArG-like element sequence. We
performed two series of bandshift experiments. First, we
incubated the
32P-labelLed WT oligonucleotide corresponding
toCFTR-CArG-likeelementsequence(asindicatedinTable2)
with bacterially expressed SRF. As shown in Figure 3A
(lane 3), EMSA revealed a recombinant SRF–WT duplex.
As shown in Figure 3A (lane 5), bands deﬁned as the
CFTR-CArG-like-SRF complex disappeared when 100-fold
molar excess of speciﬁc competitor containing the consensus
SRE motif, derived from human c-fos promoter (56), was
added. In contrast, competition by an irrelevant oligonuc-
leotide (noted UC) did not appear to signiﬁcantly alter the
complex suggesting speciﬁcity of binding (lane 6). To conﬁrm
precisely the identity of protein binding in the minimal CFTR
promoter (from –121 to –83 bp), bacterially expressed SRF
was preincubated with anti-SRF antibody before incubation
with
32P-labelled probe. As shown in Figure 3A (lane 4),
bands corresponding to CFTR-CArG-like-SRF complex dis-
appeared, and more slowly migrating bands appeared when
anti-SRF antibody was added. To verify the antibody speci-
ﬁcity, control experiments were performed either in the
absence of the SRF protein (Figure 3A, lane 7) or in the pre-
sence of an irrelevant antibody (Figure 3A, lane 8). These
results demonstrate that the CFTR-CArG-like element is a
bona ﬁde SRF-binding site. Second, we performed additional
EMSA with the WT oligonucleotide, as main binding target,
and nuclear extracts from both epithelial and muscle cells
(Figure 3B). While three nucleoprotein complexes were
formed from nuclear extracts of Beas2B and C2C12 cells
on the WT probe, ﬁve complexes were detected from A549
cells. Each nuclear protein complex was designated by an
upper case relative to nuclear lysate followed by a Roman
numeral indicating its position into the gels. The binding
speciﬁcity of the different complexes was examined by com-
petition analyses with both speciﬁc and non-speciﬁc unlabeled
oligonucleotides (Figure 3B, lanes 2–4). Although a few
non-speciﬁc binding activities were observed, complexes
BII, BIII, AIII, AV, CI, CII and CIII were efﬁciently competed
with an excess of both WT and c-fos SRE unlabeled speciﬁc
competitors indicating binding speciﬁcity (Figure 3B, lanes 2
and 3, respectively). Control experiments including an irrel-
evant oligonucleotide did not reveal any change in electro-
phoretic proﬁles (Figure 3B, lanes 4). To evaluate whether the
SRF protein contributes to the formation of nucleoprotein
complexes interacting with the CFTR-derived SRF site, we
used a speciﬁc antibody against the SRF protein. Although the
incubation with the anti-SRF antibody apparently failed to
give any discrete supershift from various sources of nuclear
proteins, a signiﬁcant decrease of speciﬁc complexes was
observed (Figure 3B, lanes 6). This effect seemed to be spe-
ciﬁc because none of these nuclear protein complexes was
supershifted or abolished when a non-speciﬁc antibody was
used(Figure3B,lanes7).Controlexperimentscontainingonly
the anti-SRF antiserum and the radiolabeled WT oligonuc-
leotide did not reveal any binding activities (Figure 3B,
lanes 8). In addition, supershift assays performed with the
radiolabeled c-fos SRE oligonucleotide instead of the WT
probe showed that bands corresponding to SRE–SRF complex
disappeared and more slowly migrating bands appeared
(Figure 3B, lane 10). The absence of supershift for speciﬁc
WT binding complexes (Figure 3D, lanes 6) may be explained
if the epitope recognized by the anti-SRF antibody is part of
(or located near) the CFTR-CArG-like DNA-binding site.
Antibody binding would compete DNA binding, resulting
in a signiﬁcant decrease or total disappearance of CArG-
like complexes rather than in supershifted complexes. Altern-
atively, if the interaction between the CFTR-CArG-like
DNA-binding site and the SRF protein is insufﬁciently strong,
it could be not as stable as the one observed with the SRE
probe (Figure 3B, lane 10) to be detected as a supershift in gel
retardation assays. On the one hand, other DNA-binding pro-
teins that are potentially part of this complex could interfere
with the antibody’s access to SRF protein. Taken together,
these EMSA studies establish SRF-binding CArG-like box
within the minimal promoter of the human CFTR gene.
SRF binds the CArG-like motif of the CFTR
minimal promoter within intact chromatin under
physiological conditions
Although there is extensive evidence that SRF can bind to
CArG-like elements in in vitro assays and that it is involved
in transcriptional regulation through CArG elements in
reporter assays in cultured cells with a typical epithelioid
morphology (53),there is a lack of direct evidence for involve-
ment of SRF in transcription of the endogenous CFTR gene
within the context of intact chromatin. To directly address
whether SRF also binds in vivo, ChIP was carried out in
bronchial epithelial cells. For this purpose, DNA-binding pro-
teins of Beas2B epithelial cells were covalently linked to
genomic DNA by treatment of the cells with formaldehyde.
Cross-linked chromatin was immunoprecipitated with either
speciﬁc or irrelevant antibodies, anti-SRF and anti-HA,
respectively. The precipitated chromatin DNA was then puri-
ﬁed and ampliﬁed by PCR with speciﬁc primers of the target
sequences (Table 1). The promoter of b-globin gene, which
lacks CArG elements, was used as negative control (Figure 4,
row A). The skeletal b-actin promoter sequence, which
contains at least a consensus SRF-binding site, was used as
positive control (Figure 4, row B). As expected, PCR signals
were obtained when the DNA/protein adducts were immuno-
precipitated with an anti-SRF antibody from both Beas2B
(Figure 4, rows B and C, lane 1) and A549 (data not
shown) epithelial cell lines. In contrast, the negative controls,
in which immunoprecipitation was performed with an irrelev-
ant antibody (Figure 4, rows A–C, lane 3) or without antibody
(Figure 4, rows A–C, lane 2), did not show any PCR signal.
These results were reproduced in several independently
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Figure 3. SRF is a component of CFTR-CArG-like binding complexes. (A) EMSAs were performed with a radiolabeled oligonucleotide encompassing the studied
CFTR-CArG-like motif (noted WT, see Table 2) and bacterially expressed SRF (lane 3). Competition assays were carried out using a 100-fold molar excess of two
specificcompetitors,notedWTandSRE(lanes2and5,respectively).UC(lane6)indicatesunspecificcompetitorthatisusedasnegativecontrol.Supershiftassays
werecarriedoutusingeitheraspecificantibody(lane4)oranirrelevantantibody(lane8).ThearrowSSindicatestheAb-supershiftedcomplex.Neithertheretarded
nor the supershifted complexes were found when the
32P-labeled WT double-stranded oligonucleotide was incubated either only with the binding buffer (lane 1) or
with specific anti-SRF antibody in the absence of purified SRF protein (lane 7). (B) EMSAs were performed with WT
32P-labeled probe in the absence of proteins
(lanes 1) or with nuclear extracts (lanes 5) isolated from Beas2B (upper panel), A549 (middle panel) and C2C12 cells (lower panel). Three or five nuclear protein
complexesweredetectedanddesignatedbyacelltype-dependentupper-casetotheleftofautoradiograms.Somebindingreactionmixturesincludeda100-foldmolar
excessoftheindicatedcoldprobes(lanes2–4).Immunologic assayswereperformedwitheitheranti-SRFAb(lanes6),oranti-HAasirrelevantantiserum(lanes7).
As a control, the
32P-labeled WT probe was incubated with anti-SRF Ab without nuclear extracts (lanes 8). In additional control experiments, radiolabeled SRE
double-strandedoligonucleotidecorrespondingtotheSREbindingsiteofthec-fospromoterwassubjectedtoEMSAswithnuclearextractsfromBeas2Bcells(upper
panel)intheabsence(lane9)orpresenceofanti-SRFantiserum(lane10).Nuclearproteincomplexesthatweresignificantlydecreasedorsupershiftedwithanti-SRF
Ab are indicated.
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CArG-like binding site identiﬁed within the CFTR minimal
promoter binds SRF in vivo, in bronchial cell lines.
The human minimal CFTR promoter shows activity
in both epithelial and muscular cells
As the SRF transcription factor is thought to mainly mediate
the tissue-speciﬁc transcription in muscular cells, we ﬁrst
assessed the activity of the minimal CFTR promoter in both
epithelial and muscular cell types. We therefore addressed the
ability of the WT-pGL3 construct, previously described (12)
to drive the expression in Beas2B, A549 and C2C12 cells. As
shown in Figure 5A, an efﬁcient transcription of the CFTR
promoter could be readily observed in all three cell lines
compared with monkey kidney ﬁbroblasts (COS-7), which
are negative for CFTR expression (36,37). Surprisingly, the
activity of the minimal CFTR promoter in C2C12 cells was 4
to 5.5 times higher than that observed in Beas2B and A549
cells, respectively. Although the expression of the CFTR pro-
tein was previously evidenced in some muscle cells (57–59),
it has never been investigated in mouse C2C12 myoblasts.
Therefore, we investigated the CFTR expression at both
mRNA and protein levels. To examine CFTR mRNA expres-
sion in mouse myoblasts (C2C12), total RNA isolated from
epithelial and non-epithelial cells was analyzed via RT–PCR
with CFTR-speciﬁc primers (Table 1). As shown in Figure 5B,
while no PCR product for CFTR was seen with COS-7 cells,
the expected CFTR ampliﬁed product was obtained for both
epithelial (A549 and Beas2B) and muscular (C2C12) cell
lines. No product was detected in the absence of reverse tran-
scriptase or RNA (noted No RT or No RNA, respectively).
Although the HPRT PCR control showed non-equivalent
amounts of cDNA used in the different PCRs, densitometric
analysis revealed that C2C12 cells contained an appreciable
amount of CFTR mRNA. Further determination of CFTR
expression in C2C12 myoblasts was conducted by western
blot analysis (Figure 5C). Caco-2 cells were used as positive
controlandCOS-7 asnegativecontrol.AsshowninFigure5C,
while mature fully glycosylated band C CFTR was observed
in A549, Beas2B and C2C12 cells, the core glycosylated
band B CFTR occurred at the same molecular mass only in
a subset of cell lines, indicative of potential variations
in glycosylation process. To rule out the possibility of anti-
bodies cross-reactivity or non-speciﬁc labeling, indirect
immunoﬂuorescence analysis was performed with another
anti-CFTR antibody, L12B4 (Figure 5D). As expected, the
Caco-2 cell line used as a positive control showed strong
immunoreactivity for CFTR protein (Figure 5D, row D). In
contrast, and as expected,COS-7 cells used as negative control
did not stain with this anti-CFTR antibody (Figure 5D, row E).
No staining was detected when the primary antibody was
omitted (Figure 5D, row F). The comparison of immuno-
ﬂuorescence images between epithelial (Figure 5D, row A,
B and D) and muscular (Figure 5D, row C) cells provides
evidence that CFTR is signiﬁcantly expressed in C2C12 myo-
blasts. However, because the indirect immunoﬂuorescence
experiments were performed in permeabilized cells, they do
not distinguish between CFTR that is located in the apical
membrane and CFTR that is located in a vesicular pool just
beneath the apical membrane. These ﬁndings, together with
the transcriptional activities presented above, suggest that the
minimal CFTR promoter might contain tissue-speciﬁc enhan-
cer(s) as well as repressive cis-regulatory elements that have
the ability to mitigate the activity of the CFTR promoter
between epithelial and non-epithelial lineages. Because CF
affects mainly epithelial tissues and Beas2B consistently
yielded higher enhancer activity than A549, we restricted
subsequent studies to this bronchial epithelial cell line.
Effects of SRF on the proximal CFTR promoter
To assess whether SRF protein might affect CFTR transcrip-
tional regulation, we took two related approaches. First, we
co-transfected either exogenous full-length SRF or truncated
SRF mutants with the wild-type CFTR minimal promoter.
Second, we utilized a siRNA approach to ask whether a reduc-
tion in endogenous SRF levels could affect basal CFTR acti-
vation. Luciferase assays were carried out in Beas2B cells
using the indicated SRF expression vectors and the WT-
pGL3luciferase reporter construct (Figure 6B, left panel).
The 3XSRE-fos TATA-Luciferase reporter gene was used
as positive control because its transcriptional activity is
highly dependent on SRF binding (Figure 6B, right panel).
As expected, while this synthetic promoter containing several
consensus SREs was markedly and signiﬁcantly activated
(>2-fold) by forced expression of full-length SRF protein
(pHiv-SRF) (Figure 6B, right panel), truncated SRF mutants
either containing only the amino acids 133–264 corresponding
to DNA-binding domain of SRF (pHiv-DBD-SRF), or deleted
of amino acids 153–165, an essential part for the DNA binding
(pHiv-DN-SRF) induced modest but signiﬁcant decrease of
SRE activity ( 10% and  30%, respectively). When these
SRF expression vectors were transiently co-transfected with
the WT-pGL3 luciferase reporter construct, the trans-activator
effect of SRF was notably reduced. Indeed, overexpression
of full-length and dominant-negative (pHiv-DN-SRF) SRF
proteins resulted in  50% increased and  30% decreased
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Figure 4. ChIP analysis of SRF binding to the endogenous CFTR minimal
promoter. Chromatin immunoprecipitation was carried out as described in
Materials and Methods. Sheared DNA/protein complexes were immunopreci-
pitated by usingeither an anti-SRFAbor anirrelevantanti-HA Ab.Then,PCR
was carried out to detect the endogenous CArG regions in immunoprecipitated
chromatin fragments. Target promoter sequences are indicated as follow: row
A,b-globin;rowB,b-actin;rowC,CFTR.Lane1showsamplificationoftarget
sequences in immunoprecipitated chromatin fragments with anti-SRF Ab.
Lanes 2 and 3: PCR amplification of control samples, without Ab or with
an irrelevant Ab. Lane 4 shows amplification of 1:100dilutionsamples of total
input DNA for immunoprecipitation.
5280 Nucleic Acids Research, 2005, Vol. 33, No. 16of luciferase activity, respectively (Figure 6B, left panel).
Unexpectedly and inconsistent with previous study (60), the
pHiv-DBD-SRF construct induced  40% increase of the
WT-pGL3 luciferase activity. This results disparity may be
explained by the fact that the c-fos promoter study (60)
assessed the DBD–SRF domain activity via microinjection
of corresponding truncated SRF polypeptide. Perhaps, the
best explanation for this increased activity is that the DNA-
binding domain of SRF, also called MADS box, is sufﬁcient
for transcriptional activation of some SRF-dependent genes
because it mediates interactions with accessory co-activators
(61). These results suggest that neither of the regions outside
the MADS box, N- or C-terminal, appear essential for trans-
activation of the CFTR promoter by SRF.
To further establish the role of SRF in mediating the
increase in CFTR gene transcription, we performed siRNA
experiments (Figure 6C). To demonstrate the efﬁcacy of spe-
ciﬁc SRF siRNA construct, Beas2B cells were co-transfected
with either control or SRF siRNA plasmids and western
blots were performed to analyze levels of SRF in these
cells. Densitometric analysis of western blot showed that
endogenous SRF levels were strongly reduced in the presence
of the SRF siRNA plasmid (Figure 6C, left panel). Then,
control and SRF siRNA plasmids were co-transfected into
Beas2B cells with either the WT-pGL3 or the 3XSRE luci-
ferase reporter construct. As shown in Figure 6C (right panel),
reduction of endogenous SRF protein level decreased the
activity of both wild-type CFTR promoter and 3XSRE-fos
TATA-Luciferase reporter constructs by  25%.
Taken together, these ﬁndings indicate that endogenous
SRF into bronchial epithelial cells normally function as tran-
scriptional coactivator for the CArG-mediated transactivation.
However, we found that SRF activated the CFTR promoter
less well than the SRE-containingsynthetic promoter,suggest-
ing that the CArG-like element mediated CFTR transcriptional
activation probably required other bridging or co-activating
factors.
TheCArG-likeelementcontainedinthehumanminimal
CFTR promoter is important but not sufficient for
basal transcriptional activity in Beas2B cells
To assess the transcriptional relevance of the CArG-like
binding sequence of CFTR minimal promoter, mutants were
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Figure5. AnalysisofCFTRminimalpromoteractivityandCFTRexpression.(A)CFTRminimalpromoteractivitiesinBeas2B,A549,C2C12andCOS-7celllines.
Theamountof1.8mgofWT-pGL3constructwasco-transfectedtogetherwith0.2mgofinternalcontrolpRL-SV40containingRenillaluciferase.TheemptypGL3-
Basicvectorwastransfectedasanegativecontrol.Normalizedluciferasevaluesareillustratedasrelativelightunits.Themeanoftwoindependentplasmidsprepsand
eachexperimentwithstandarderrorsisshown.Theexperimentalvalueforluciferaseactivityrepresentedthemean ± SDoffourseparateexperimentsintriplicates.
(B) RT–PCR analysis of CFTR mRNA expression. Total RNA was harvested from the indicated cell lines and subjected to PCR as described in ‘Materials and
Methods’. cDNA derived from COS-7 was used as a negative control. Samples without reverse transcriptase (noted No RT) or with an H2O no-template reaction
(noted No RNA) were used as additional negative controls. Samples were also amplified for HPRT to control for RNA degradation during DNase treatment and
reversetranscription.DensitometricanalysisofCFTRbandsintensitywasperformedwithrelativeHPRTmRNAexpressioninBeas2Bbronchialepithelialcells.(C)
Western blot analysis. Whole cell proteins extracts prepared from indicated cells were subjected to electrophoresis with 7% SDS–PAGE gel and transferred to
supported PVDF membrane. CFTR immunoreactivity was detected using 24.1 anti-CFTR Ab as the primary antibody. Positions for the core glycosylated (band B)
andmaturefullyglycosylatedCFTR(bandC)areindicatedbythearrowsattheright.Numbersbelowtheb-actinpanelindicateintensityvaluesofintegratedoptical
densitiesofthe matureandimmatureCFTR bandsnormalizedoverthe corresponding b-actin bandsand expressedrelative to the Beas2Bcontrols bands,whichare
set to 1. (D) Indirect immunofluorescence analysis. The A549, Beas2B, C2C12, Caco-2 and COS-7 cells (rows A–E, respectively) were fixed, permeabilized, and
thenstained withthe L12B4 anti-CFTRAb, followedby the appropriatesecondaryantibodyas described in ‘Materialsand Methods’.Left panel,cells were stained
withCy3-conjugatedsecondaryantibody(red).Middlepanel,cellswerecounterstainedwithDAPI(blue)fornuclearstaining.Rightpanel,shownismergeofCFTR
immunostaining and DAPI. Row F, Background immunofluorescence obtained in the absence of the primary antibody.
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Figure 6. Effect of SRF on the activity of CArG-containing CFTR minimal promoter. (A) Schematicrepresentation of different SRF constructsanalyzed. The SRF
fragmentsshownwere clonedintothe pHivexpressionvectorasindicatedin ‘Materials andMethods’.The positionofthe MADSbox containingthe DNA-binding
domainanddimerizationdomainofSRFisdepictedbyblackrectangle.WTSRFconstructencodesahumanfull-lengthSRFopenreadingframe.DBDSRFconstruct
encodesonlytheDNA-bindingdomainofSRF.DNSRFdeletionconstructencodesfull-lengthSRFdeletedofanessentialpartfortheDNAbinding.(B)Expression
ofexogenousSRFinBeas2Bcells.Cellswereco-transfectedwiththeWT-pGL3luciferasereporterplasmid(leftpanel)togetherwiththeemptypHivvector,pHiv-
SRF, pHiv-DBD-SRF or pHiv-DN-SRF constructs, as indicated below the bar diagram. As a positive control, 3XSRE luciferase reporter plasmid was used. In each
experiment,aRenillaluciferaseexpressionplasmidwasincludedtonormalizefortransfectionefficiency.Foreachreporterplasmid,luciferaseactivity(mean ± SE)
isderivedfrom4to7differenttransfectionexperimentsperformedintriplicate.Theerrorsbarsindicatethestandarddeviations.Theluciferaseactivityvalue100was
assignedtothesamplesco-transfectedwiththeindicatedreporterplasmidandtheemptypHivexpressionvector.Statisticalsignificanceisreferredtodifferenceswith
the activity obtained with empty expression vector. *, P < 0.05 versus WT or 3XSRE. (C) Effects of SRF siRNA on CFTR promoter activity and expression in
Beas2B epithelial cells. Left panel: Beas2Bcells were co-transfected witheither humancontrol siRNA vector or plasmidencoding SRF siRNA as indicated.Forty-
eight hours following transfection, total proteins were harvested and analyzed by western blotting. Densitometric analysis showed a substantial decrease of
endogenousSRF.Rightpanel:theluciferaseactivityvalue100wasassignedtothesamplesco-transfectedwiththecontrolsiRNA.*,P < 0.05versusWTor3XSRE.
5282 Nucleic Acids Research, 2005, Vol. 33, No. 16performed to create either more consensus CArG element or
degenerated motif (Table 1). We used the D upper-case and
the C upper-case to designate the Degenerated CArG motifs
and the Consensus CArG elements, respectively. To ensure
the efﬁcacy of mutations in abrogating transcription factor
binding, we ﬁrst performed a series of EMSA experiments
with each CArG mutant and the WT probe (Table 2). As
expected, based on the sequence analysis, the mutations
resulting in more degenerated CArG motifs (D1, D2, D3
and D4 mutants) completely abolished SRF-binding activity
(Figure 7A, lanes 1–4), when we compared with SRF-WT
complexes (Figure 7A, lane 5). In addition, the probes con-
taining more consensus CArG boxes (C1, C2, C3, C4 and C5
mutants) bound SRF more strongly in nuclear extracts
prepared from Beas2B (Figure 7A, lanes 6–10). Inclusion
of an anti-SRF antibody partially abolished SRF-binding
activity and resulted in a slower mobility band, conﬁrming
the identity of the binding protein (Figure 7A, lane 11). Then,
minimal CFTR promoter constructs bearing the same con-
sensus and disrupted CArG boxes were tested in a transient
transfection assays in Beas2B cells (Figure 7B). Compared
with luciferase activity resulting from the WT-pGL3 con-
struct, variable increases in reporter activity are observed
when D1, D2, D3 and D4 mutant constructs, with disrupted
CArG motif, were transiently transfected. On the other hand,
mutations that create more consensus CArG element result in
either reducing or increasing in the transcriptional activity
(Figure 7B). Consistent with the preceding gel-shift results
Labeled probes
Anti-SRF Ab -- - - - - - - - - +     
 D1   D2     D3     D4     WT    C1     C2      C3      C4    C5      C3     
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 D1 D2 D3 D4      WT       C1  C2  C3  C4  C5
* *
*
* *
*
Nuclear Extract 
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B
1    2         3     4     5          6       7        8 9        10 11   
Figure 7. The CFTR-CArG-like element is not sufficient for basal transcriptional activity in Beas2B cells. (A) EMSA analysis with nuclear extracts from SRF
protein-enriched Beas2B cells using mutatedlabeled oligonucleotide probes (sequenceslisted in Table 2). Ab against SRF was included as indicated (lane 10). The
arrowSSindicatesthesupershiftedcomplexes.(B)BasaltranscriptionalactivityofCArGvariantsoftheCFTRpromoter.LuciferaseactivityobtainedwiththeWT-
pGL3luciferaseconstructwasdefinedas100%,andrelativeluciferaseactivitiesfrommutantconstructsareexpressedasapercentageofthisvalue.Fireflyluciferase
activity was normalized with respect to Renilla luciferase activity. The errors bars indicate the standard deviations. *, P < 0.05 versus WT.
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5284 Nucleic Acids Research, 2005, Vol. 33, No. 16revealing an uncharacterized protein/DNA complex with
slightly slower mobility and variable intensity compared
with the SRF–DNA complex, these ﬁner mutagenesis studies
suggest that both co-activators and co-repressors might
interact with the studied promoter sequences. Taken together,
these data demonstrated that the CFTR-CArG-like element
alone is not sufﬁcient to confer basal transcriptional activation
of the CFTR gene.
Functional antagonism between SRF and YY1 through
competition for the CFTR-CArG-like binding
As a further means of establishing the role for SRF-binding
CArG boxes in mediating either the CFTR-enhancer or
silencer activity observed with the different minimal CFTR
promoter mutants, we performed additional computational
analyses. Sequence analysis of CArG boxes and their imme-
diate ﬂankingsequencesshowedthatC1,C3andC4constructs
contain consensus binding sites for a number of transcription
factors, in addition to SRF, including the transcription
factor YY1. These ﬁndings with previous work (12) have
particularly evoked our interest to examine the role of YY1
in SRF-mediated CFTR transcriptional activity.
In a ﬁrst set of experiments, we evaluated whether the YY1
factor contributes to the formation of nucleoprotein complexes
interacting with the WT, C1, C3 and C4 radiolabeled probes.
As shown in Figure 8A, incubation with speciﬁc anti-YY1
antibody resulted in either a signiﬁcant decrease or total
disappearance of some complexes normally formed between
the CArG boxes and a component of Beas2B nuclear extracts,
establishing DNA binding between YY1 and the sequences
tested. As expected, control experiment performed with radio-
labeled probe, D2, devoid of any YY1 binding site and the
anti-YY1 antiserum did not reveal any change in electrophor-
etic proﬁles indicating speciﬁcity of the YY1 binding. Thus,
these EMSAs demonstrated that the CFTR-CArG-like (WT
probe) and more consensus CArG elements (C1 < C3 < C4)
served as binding site for at least two distinct nuclear factors,
namely SRF and YY1 from bronchial epithelial cells.
Then, to determine whether the interaction of these two
factors with their target DNA (CFTR-CArG-like or more
consensus CArG sequence) was either mutually inclusive or
exclusive, EMSAs were conducted using bacterially expressed
SRF and nuclear extracts prepared from Beas2B cells trans-
fected with a YY1 expression vector as a source of YY1 DNA-
binding activity. As shown in Figure 8B, the YY1-binding
complex was signiﬁcantly reduced by increasing SRF bind-
ing activity, suggesting their mutually exclusive binding to
CArG sites.
Consistent with other studies (32,62), these EMSAs results
suggested as a working hypothesis that both SRF and YY1
likely act as functional competitors in the CFTR promoter
activity. Since the minimal CFTR promoter is activated by
SRF and knowing from previous studies (30–33) that YY1
negatively regulates some promoter containing CArG ele-
ments, it seemed logical to ﬁrst assess whether YY1 could
also repress the CFTR promoter. We asked whether CArG-
like-binding site in the CFTR promoter acted as negative
regulatory elements. Several CFTR promoter reporter con-
structs containing either CArG-like (namely, WT) or con-
sensus CArG element (C1, C3 and C4) were co-transfected
with SRF and/or YY1 expression vectors into Beas2B cells.
As shown in Figure 8C, while co-transfections with SRF
alone resulted in 1.5- to 2-fold luciferase activation, forced
expression of YY1 protein caused a strong decrease in reporter
activities ( 50–75% of the control luciferase value). There-
fore, we wanted to determine the functional relationship of
both factors in the CFTR activity regulation. Transient co-
transfections analysis of combination of protein expression
vectors showed that over-expression of SRF either did not
restore (Figure 8C, panel with the WT and C4 reporter con-
structs) or only very slightly raised the YY1-repressed reporter
activities (Figure 8C, panel with the C1 and C3 reporter con-
structs). These ﬁndings are consistent with results obtained
from co-transfections performed with the YY1 expression
vector alone and previous alpha-actin promoter studies
(30–33), in which YY1 acted as a strong repressor. Taken
together, these data suggested functional antagonism between
SRF and YY1 through DNA-binding competition.
Identification of multiple CArG binding sites in
the non-coding regions of the human CFTR gene and
assessment of their putative functional importance
To assess the putative importance of CArG motifs in the
human CFTR expression regulation, we performed an in silico
inspection of additional sequences upstream of the minimal
promoter and in the intronic regions. Four CArG binding
sites were found in the CFTR promoter regions, and seven
in the intronic regions. The distribution and the positions of
these putative binding sites for SRF are shown in Figure 9A.
Then, to conﬁrm the computational predictions, we used
several approaches. First, the nucleotide regions harboring
these predicted cis-acting elements were analyzed for conser-
vation in the cow, as physiologically relevant transcription
factor binding sites are frequently conserved in the non-
codingregionsof orthologousgenes (49,63).Second, the SRF-
binding sites were tested by EMSAs and also for one of them
by ChIP.
We showed that all the predicted CArG elements occur
in highly conserved CFTR non-coding regions (Figure 9B),
which may contain tissue-speciﬁc transcription factors (5).
We provided evidence that the majority of in silico predicted
CArG motifs form speciﬁc DNA–protein complexes with
Figure 8. Functional interplay between SRF and YY1. (A) YY1 binding to CFTR-CArG elements. Nuclear extracts from Beas2B cells were incubated with
32P-
labelledoligonucleotideprobecontainingeitherCArG-like(notedWT),consensusCArGbox(notedC1,C3andC4)inthepresenceorabsenceofspecificantibody
raised against YY1 as indicated. D2, which contain neither CArG element nor YY1 site, is included as negative control. Arrows indicate the position of YY1.
(B)MutuallyexclusiveDNA-bindingactivityofYY1versusSRFtotheCFTR-CArGsite.ThesamelabeledCArGoligonucleotidesthatthoseusedinpanelAwere
incubatedwithYY1-transfectedBeas2Bnuclearextracts(5mg)in thepresenceof increasingamountsofbacterialpurifiedSRF(100–1000ng).Arrowsindicatethe
position of SRF and YY1. (C) Functional antagonism between SRF and YY1. Beas2B were transfected with constructs containing either the CFTR-CArG-like
element (noted WT) or consensus CFTR-CArG-boxes (noted C1, C3 and C4), in the presence of SRF and/or YY1 expression vectors. Luciferase activities were
normalizedfortransfectionefficiencytotheRenillaluciferaseusedasinternalcontrol.Theluciferaseactivityvalue100wasassignedtosamplesco-transfectedwith
theindicatedreporterplasmidandtheemptyexpressionvector.Themean ± SDfromatleastthreeindependentexperiments isrepresented.*,P < 0.05versusWT,
C1, C3 or C4.
Nucleic Acids Research, 2005, Vol. 33, No. 16 5285bacterially expressed SRF protein (Figure 9C, left panel). We
alsodemonstrated byusingBeas2B nuclearextracts andsuper-
shift assays that some of these CArG elements bound in vitro
SRF protein (Figure 9C, right panel, lanes 1, 3, 7 and 9).
Finally, additional ChIP experiments indicated that the only
tested CArG element, located at –2373 bp in the CFTR
promoter, bound SRF in chromatin from intact cultured
Beas2B cells (Figure 9D, lane 1). Collectively, these ﬁndings
support the concept that SRF may play a key role in the CFTR
expression regulation via binding to multiple CFTR CArG
elements.
DISCUSSION
While great strides have been made in CFTR research with
emphasis on the structure and function of this protein, only
incremental advances have been achieved in the ﬁeld of tran-
scriptional regulation. In our previous works (12,20), we have
identiﬁed a polymorphic CArG-like site and showed that a
naturally occurring sequence variation in this motif may
enhance the basal CFTR transcriptional activity. The goal
of the present study was to better characterize the human
CFTR promoter region encompassing the CArG-like element.
CArG boxes of the human CFTR gene and the corresponding 
regions of homology in the cow
CArG Number
 
Location of 
CArG in human
  Human clone
 
Human:cow
 
Homology
  Cow clone
 
 
Upstream exon 1
      
      
1 -10.7  kb   AC000111 
8846-9031 
79% AC089992 
79372-79554 
2 -2.7  kb   AC000111 
16861-17034 
70% AC089992 
88539-88711 
3 -2.4  kb   AC000111 
17241-17491
80% AC089992 
88821-89081 
        
 Intron  1       
4  185 + 9.5 kb  AC000111 
29167-29430 
80% AC089992 
105768-106034 
5  185 + 9.9 kb   AC000111 
29699-29846 
72% AC089992 
106311-106457 
6  185 + 14.7 kb   AC000111 
34514-34681 
73% AC089992 
111573-111738 
7  185 + 20.8 kb   AC000111 
40563-40861 
76% AC089992 
126635-126931 
        
 Intron  3       
8  405 + 1 kb   AC000111 
49422-49657 
80% AC089992 
13843-14064 
        
 Intron  10       
9  1716 + 23 kb  AC000111 
122060-122341 
75% AC089993 
66259-66531 
        
 Intron  17a       
10  3271 + 0.7  kb
 
AC000061 
1141-1494
73% AC089993 
100451-100785
5' 3'
12 3 4 5 67 8 9 1 0
-108
CFTR CArG-like 
box -10.7kb
-2.7kb
-2.4kb
185+9.5kb
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3271+0.7kb
Transcription 
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B
5286 Nucleic Acids Research, 2005, Vol. 33, No. 16Comparisons of nucleotide sequences of this CFTR pro-
moter region in eight mammalian species representing three
different orders (Primates, Artiodactyla and Lagomorpha)
revealed high levels of conservation of the minimal promoter
region, as described previously (64). However, the CArG-like
element (GC(T/A)6GG), which does not conform to the
authentic CArG box (CC(T/A)6GG), is absent from three
species (sheep, cow and rabbit). Even though this motif occurs
in only a subset of the input sequences, it does not necessarily
mean that it is of no functional importance. Instances of cis-
regulatory elements being species-speciﬁc have been already
reported for the CFTR gene (50). More generally, it is well
known that some transcription factors can tolerate more than
one type of nucleotide at a given position of the binding site.
Instances of substitutions in both the central core of the CArG
element and the highly conserved contact points for SRF,
at the terminal ends, not impairing SRF binding have been
previously reported (48,65–68). Taken together, these data
support the notion that the CFTR-CArG-like element has
possible important implication in the CFTR transcriptional
regulation.
Interestingly, analysis of SRF expression has revealed relat-
ively high expression levels of SRF protein in the bronchial
epithelial cells (Figure 2), as shown in other differentiated
epithelial cells (27). Accumulating evidence supports the
concept that SRF could contribute to the CFTR expression
regulation. In addition to regulating growth-responsive genes
and numerous muscle-speciﬁc genes (22,69), SRF is also
described as a key trans-binding factor in various important
physiological events. For example, SRF has been shown to
regulate pulmonary development in Drosophila (28), to pro-
mote both re-epithelialization and muscular structure restora-
tion during gastric ulcer healing (70) and more recently to be
involved in the regulation of endoplasmic reticulum-targeted
gene (67). Therefore, it was relevant to examine the potential
role of SRF on the CFTR transcriptional activity.
Inthepresentstudy,wedemonstrated thatCFTR-CArG-like
element forms speciﬁc DNA–protein complexes that include
SRF protein as part of the complex, in vitro and in vivo
(Figures 3 and 4). We have investigated the expression driven
by the proximal human CFTR promoter in a pGL3 construct in
both epithelial and myoblasts lines. Results of our transient
transfections of 3XSRE-fos TATA and WT-pGL3 luciferase
reporter genes showed that the human minimal CFTR pro-
moter encompassing a CArG-like motif was sufﬁcient to
drive the expression in both cell types (Figure 5). Consistent
with otherstudiesshowingCFTR expressioninsmoothmuscle
tissue (71,72), our results demonstrated that the human CFTR
minimal promoter had the ability to drive the expression in
muscle lineages. Our transient co-transfections analyses per-
formed with full-length and dominant-negative SRF forms
expression vectors, and also speciﬁc SRF siRNA constructs
(Figure 6, panels B and C) provide the ﬁrst evidence for
a positive role of the SRF protein in the regulation of the
human CFTR promoter. However, the SRF-induced CFTR
transactivation, though signiﬁcant, is relatively modest.
These data with the results of ﬁner mutagenesis studies presen-
ted in Figure 7 support the concept that SRF alone is not
sufﬁcient to drive the basal expression of the CFTR gene.
As suggested by other previous studies (73–75), it is likely
that additional factors might be required to optimally drive
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Figure 9. The CFTR gene untranslated regions contain multiple SRF-binding
sites (CArG-boxes). (A) Schematic drawing of CFTR gene shows the exons
(circles)andthelocationoftheputativeCArGboxesinthenon-codingregions,
including that identified in the minimal CFTR promoter. (B) The CFTR gene
non-coding regions encompassing the putative CArG elements were analyzed
for conservation in the cow. Species homology and positions of the conserved
sequence within BAC clones are indicated, as reported in a recent work (49).
(C) Comparative binding of SRF to CFTR CArG boxes. Each promoter and
intronic CArG box-containing oligonucleotide (see Table 2) was radiolabeled
and purified as described in ‘Materials and Methods’. Upper panel, binding
reaction was performed with bacterially expressed SRF. Ab against SRF was
included as indicated. Arrow indicates specific DNA–SRF complexes and
SS indicates the Ab-supershifted complexes. Lower panel, EMSA analysis
with nuclear extracts from Beas2B cells using mutatedlabeled oligonucleotide
probes. (D) ChIP analysis of SRF binding to the endogenous CArG regions.
Lane 1 shows amplification of target sequence in immunoprecipitated
chromatin fragments with anti-SRF Ab. The target sequence encompasses
a CArG element, located to –2373 bp in the minimal CFTR promoter.
Lane 2 shows PCR amplification of a control sample, without Ab. Lane 3
shows amplification of 1:100 dilution samples of total input DNA for
immunoprecipitation.
Nucleic Acids Research, 2005, Vol. 33, No. 16 5287the CFTR promoter, as well as to specify the cell-type-
restricted expression. Since YY1 was previously shown to
bind the CFTR promoter (12) and a subset of SREs serve
as binding sites for YY1 (30–33), we ﬁrst evaluated this
candidate in the SRF-mediated CFTR transcriptional activity.
The data analysis suggests a functional antagonism between
SRF and YY1 through binding competition for the CFTR-
CArG-like box. However, the analysis of combinatorial co-
transfection studies, presented in Figure 8C, suggests that the
functional interplay between SRF and YY1, alone, is not suf-
ﬁcient to account for basal CFTR transcriptional activation.
Further studies will be necessary to determine whether another
player might be involved in this functional interplay and
accounted for the basal transcriptional CFTR activity observed
in the Beas2B bronchial epithelial cells.
Interestingly, we showed that, in addition to the CArG-like
element deﬁned in the minimal promoter of the CFTR gene,
there are three CArG motifs located at the 50 end of the gene
and seven are present in the intronic regions (Figure 9). We
also evidenced SRF binding to CArG elements of the endo-
genousCFTRgeneinthecontextofintactchromatin(Figures4
and 9D). Although the role of these more distal CArG boxes
has yet to be assessed, these ﬁndings are of major importance,
since it has been shown that optimal activity of the SRF-
dependent target genes may require a number of CArG
boxes, including those that are deﬁned in the intronic region
(66,67,76). Moreover, as already suggested for the a-actin
promoters (32,74), perhaps the presence multiple CArG ele-
ments in the CFTR gene with cooperative binding events
might be essential for SRF to prevent YY1 from binding to
the CFTR promoter. Clearly, further studies are needed to
directly investigate the role of these multiple CArG elements
in transcriptional regulation of the CFTR gene.
Taken together, our results demonstrated for the ﬁrst time
that the human CFTR promoter is a novel SRF target gene,
subject to modest but signiﬁcant SRF activation partially due
to functional antagonism between YY1 and SRF through
mutually exclusive DNA-binding activities of YY1 versus
SRF to the CFTR-CArG-like site.
A critical question is, thus, how might SRF contribute to
orchestrating cell-restricted and context-dependent programs
of CFTR gene expression? Our ﬁndings and investigations
to date clearly indicate the presence of several different under-
lying mechanisms of SRF-dependent transcriptional activa-
tion, as represented in Figure 10. These might include
association of SRF with a variety of cell-restricted co-factors
(noted in gray bubbles, Figure 10), such as MRTF-A highly
expressed in epithelial cells of the lung, kidney, colon and
testis, and MRTF-B also expressed in smooth muscle cells
(77), ternary complex factors, such as p62 and SAP-1
(25,78) and remodeling chromatin co-factors in an HAT-
dependent manner, such as the CREB-binding protein (79).
In addition, it is well known that binding of SRF to the CArG
box induces an acute bend in the DNA and that this bending
may vary with changing base compositions across the CArG
box (80). Such bending can probably facilitate interactions
with other proteins already involved in the CFTR expression
regulation, such as NF-kB (13) and C/EBP (9) and described
as interacting with SRF (81). Finally, the Ras-related
GTPases family (rac, RhoA and cdc42) might have a critical
role in the activation of SRF (82). Indeed, it is reported that
RhoA-induced SRF activation occurs through a phenomenon
of ‘actin treadmilling’ restricted to CArG-dependent genes
that do not have adjacent ETS-binding sites (e.g. smooth mus-
cle cell restricted CArG genes) (83,84). Moreover, it has been
shown that the activation of SRF may be mediated by the
NF-kB and C/EBP transcription factors (81).
These data provide the foundation for further studies on the
regulation of CFTR and will unable the rational design of
further functional studies, including various strategies aiming
to further dissect the different regulation pathways.
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